O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases

Clinical Trial Application approval…Read More

You might also be interested in reading Phantom Wallet CEO says no plans for own chain or IPO.